THE Therapeutic Goods Administration has announced that Lartruvo (olaratumab) is the first medicine to be given the tick under the new "provisional approval pathway" which came into effect last month (PD 21 Mar).
Lartruvo is an orphan drug indicated for soft tissue sarcoma, with the new pathway allowing sponsors to apply for time-limited provisional registration to give early access to promising medicines.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Apr 18
